ONXEO;Institut Curie;Centre National de la Recherche Scientifique
发明人:
申请号：
EP16183451.0
公开号：
EP3135301B1
申请日:
2011.06.21
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
